{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:37Z","timestamp":1793043097325,"version":"4.5.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"Importance<\/jats:title>It is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not adequately answer this question due to underrecruitment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the effectiveness of using methotrexate with adalimumab in people with plaque psoriasis.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This target trial emulation cohort study replicated key aspects of the OPTIMAP trial design using the British Association of Dermatologists Biologics and Immunomodulators Register between 2007 and 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Adalimumab, 40 mg, every other week monotherapy (comparator) vs adalimumab, 40 mg, every other week and methotrexate weekly, with the dosage as determined by the clinician (intervention).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the difference in the adalimumab survival function at 1 year. The secondary outcomes included differences in adalimumab survival function at 3 years; 75% reduction in Psoriasis Area and Severity Index (PASI75) at 1 year and 3 years; serious adverse events at 1 and 3 years; and adalimumab concentrations and antidrug antibodies at 1 year. Inverse probability treatment and censoring weighting were used for covariate and missing outcome adjustment. Flexible parametric survival models were fitted for survival outcomes and generalized linear models for other outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 231 and 1553 participants (754 female individuals [42.3%]) in the intervention (median [IQR] age, 43.7 [35.1-53.1] years) and comparator (median [IQR] age, 43.6 [34.2-52.0] years) arms, respectively. Drug survival for the comparator arm at 1 year was 78.1% (95% CI, 76.1%-80.2%) and the intervention arm was 79.1% (95% CI, 71.8%-87.2%), with no evidence of difference (1.0%; 95% CI, \u22127.0% to 8.9%). PASI75 at 1 year and 3 years in the comparator arm was 52.0% (95% CI, 47.7%-56.3%) and 32.4% (95% CI, 28.0%-36.8%), respectively; in the intervention arm, PASI75 was 49.4% (95% CI, 31.5%-67.3%) and 37.2% (95% CI, 16.8%-57.6%), respectively. There was no evidence of differences at 1 year and 3 years (\u22122.5%; 95% CI, \u221221.0% to 15.9% and 4.9%; 95% CI, \u221216.1% to 25.7%, respectively). There was no evidence for a difference between the 2 arms for serious adverse events and adalimumab concentrations, while the intervention arm had a lower antidrug antibody level (risk difference, \u2212123.7 AU\/mL; 95% CI, \u2212200.5 to \u221246.9).<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>The results of this cohort study suggest that there was no evidence of a difference in the effectiveness and persistence of adalimumab in people with psoriasis between monotherapy and adalimumab with concomitant methotrexate.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1463","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:35Z","timestamp":1749034835000},"page":"731","source":"Crossref","is-referenced-by-count":6,"title":["Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis"],"prefix":"10.1001","volume":"161","author":[{"given":"Zenas Z. N.","family":"Yiu","sequence":"first","affiliation":[{"name":"Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom"},{"name":"The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Leeds Dermatology Centre, Leeds Teaching Hospitals NHS Trust, Chapeltown Road, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Hampton","sequence":"additional","affiliation":[{"name":"Institute of Translational and Clinical Medicine, Medical School, Newcastle University, Department of Dermatology, Royal Victoria Infirmary and National Institute for Health and Care Research Newcastle Biomedical Research Centre, Newcastle Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom"},{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King\u2019s College London, London, United Kingdom"},{"name":"King\u2019s College Hospital NHS Foundation Trust, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom"},{"name":"The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BADBIR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BSTOP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"doi250019r1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250019r2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"doi250019r3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review.","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi250019r4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","article-title":"Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study.","volume":"139","author":"Wilkinson","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi250019r5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: myths, facts and a suggested approach.","volume":"35","author":"Tsakok","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi250019r6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"doi250019r7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3899\/jrheum.141596","article-title":"Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? data from a large observational study.","volume":"43","author":"Behrens","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"doi250019r8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"issue":"1","key":"doi250019r9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13063-017-1777-y","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.","volume":"18","author":"Busard","year":"2017","journal-title":"Trials"},{"issue":"9","key":"doi250019r10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","article-title":"Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial.","volume":"142","author":"van der Kraaij","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi250019r11","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/jdv.19089","article-title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomized controlled trial.","volume":"37","author":"van Huizen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi250019r12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"3","key":"doi250019r13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives.","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250019r14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/bjd.15027","article-title":"Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"176","author":"Iskandar","year":"2017","journal-title":"Br J Dermatol"},{"issue":"12","key":"doi250019r15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"doi250019r16","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"doi250019r17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamadermatol.2020.4202","article-title":"Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register.","volume":"157","author":"Yiu","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"8","key":"doi250019r18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3899\/jrheum.151009","article-title":"Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial.","volume":"43","author":"Kaeley","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"doi250019r19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi250019r20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clinthera.2018.01.002","article-title":"Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO trial.","volume":"40","author":"Goss","year":"2018","journal-title":"Clin Ther"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2834649\/jamadermatology_yiu_2025_oi_250019_1752181131.62824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:00:24Z","timestamp":1752678024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2834649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1463","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}